. Author manuscript; available in PMC: 2010 Jun 1.

Published in final edited form as: Pharmacogenomics. 2009 Aug;10(8):1243–1255. doi: 10.2217/pgs.09.71

Table 3.

African–American CYP2C9 allele frequencies.

Allele	This study (n = 600)		Blaisdell (2004) [33](n = 28)^‡	Takahashi (2006) [5] (n = 128)	Momary (2007) [30] (n = 202)	Kealey (2007) [55] (n = 336)	Limdi (2008) [29] (n = 536)
Allele	Frequency	95% CI	Blaisdell (2004) [33](n = 28)^‡	Takahashi (2006) [5] (n = 128)	Momary (2007) [30] (n = 202)	Kealey (2007) [55] (n = 336)	Limdi (2008) [29] (n = 536)
CYP2C9*1	0.867	0.839–0.894	0.831^‡	0.953	0.946	0.961	0.937
CYP2C9*2	0.028	0.015–0.042	0.000	0.000	0.030	0.036	0.013
CYP2C9*3	0.020	0.009–0.031	0.000	0.008	0.015	0.003	0.019
CYP2C9*4	0.000	0.000–0.000	0.000	0.000	ND	ND	ND
CYP2C9*5	0.015	0.005–0.025	0.000	0.008	0.010	ND	0.009
CYP2C9*6	0.010	0.002–0.018	0.000	0.008	ND	ND	0.007
CYP2C9*8	0.047	0.030–0.064	0.036	ND	ND	ND	ND
CYP2C9*11	0.013	0.004–0.023	0.000	0.023	ND	ND	0.015
CYP2C9*13	0.000	0.000–0.000	0.000	ND	ND	ND	ND

^‡

This study performed CYP2C9 sequencing on 14 or 15 African–American samples. Of these, 1 of 14 had CYP2C9*8, 4 of 15 (0.133) had CYP2C9*9 (p.H251R) and several noncoding or synonymous variants were identified. The frequency of CYP2C9*1 was therefore calculated as 1 – the sum of CYP2C9*8 and *9.

n: Number of alleles; ND: Not determined.